Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I d...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Haematol
Prif Awduron: Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2019
Pynciau:
Haematological Malignancy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6772147/
https://ncbi.nlm.nih.gov/pubmed/31124580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15969
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg